Clinical trial
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic…
NCT00310492 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00310492 |
|---|---|
| Title | Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis |
| Official title | Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Biological |
| Interventions | subcutaneous immunotherapy |
| Enrollment | 154 |
| Start date | Apr 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Apr 4, 2006 |
| Last update posted | Dec 29, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: